Originator Organization |
Active Organization- |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC50H62ClN11O6S2 |
InChIKeyYGQREOJIRFCRKQ-ZIBKGDFVSA-N |
CAS Registry2376047-73-1 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | China | 20 Sep 2019 | |
| Neoplasms | Preclinical | China | 20 Sep 2019 | |
| Neoplasms | Preclinical | China | 20 Sep 2019 |





